Boris Pasche, M.D., Ph.D., FACP

Specialties

Oncology - Medical

Board Certification

American Board of Internal Medicine - Medical Oncology, Hematology

Multidisciplinary Team

Gastrointestinal and Neuroendocrine Oncology

Language(s) Spoken

English, French, German, Swedish

Locations

Karmanos Cancer Center
4100 John R
Detroit, MI 48201
Get Directions

Phone:1-800-KARMANOS

Call For Appointment

Podcast: Listen

Cancers Treatments

Locations

Karmanos Cancer Center

4100 John R
Detroit, MI 48201
Get Directions

Phone:1-800-KARMANOS

Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Center

31995 Northwestern Highway
Farmington Hills, MI 48334
Get Directions

Get Directions

Education

Additional Info

Dr. Pasche has served as president and Chief Executive Officer of the Barbara Ann Karmanos Cancer Institute and chair of the Department of Oncology at Wayne State University since 2023. Before joining Karmanos, he served as director of the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC), principal investigator of the NCI CCSG award, and chair of the Department of Cancer Biology from 2014 until 2022. He was the first to identify and characterize TGFBR1*6A, an in-frame deletion within TGFBR1 exon 1, which has emerged as a low penetrance tumor susceptibility allele. Dr. Pasche is the co-inventor and principal developer of a novel medical device delivering amplitude-modulated radiofrequency electromagnetic fields for systemic targeted cancer treatment. The device is FDA-approved for the treatment of patients with advanced hepatocellular carcinoma who fail first- and second-line therapy.

A native of Switzerland, Dr. Pasche earned his doctorate of medicine and doctorate of philosophy from the Karolinska Institute in Stockholm, Sweden, and another doctorate of medicine from the University of Lausanne in Switzerland. Following a postdoctoral fellowship at the Brigham and Women’s Hospital, Harvard Medical School, Dr. Pasche completed an internship and residency in internal medicine at the New York Hospital at Cornell University Medical Center. He also went on to complete a hematology and oncology fellowship at Memorial Sloan-Kettering Cancer Center and a second postdoctoral fellowship at Howard Hughes Medical Institute and Sloan-Kettering Institute for Cancer Research

Research Interests

Treatment of cancer with radiofrequency electromagnetic fields.
Cancer Genetics.
TGF-ß
Ethnic and Racial Disparities in Multiple Myeloma Education, Diagnosis, and Treatments.

Related News

December 18, 2024
IN THE NEWS: Detroit Cancer Center Unveils New Device for Treating Liver Cancer at Home

The Detroit News The TheraBionic P1 device is now available for patients who have advanced liver cancer and have failed first- and second-line therapies. Boris Pasche, M.D., Ph.D., FACP , president and CEO of the Barbara Ann Karmanos Cancer Institute, chair of the Department of Oncology at Wayne State University, and co-inventor of the TheraBionic P1 device, and Anthony Shields, M.D., Ph.D. , medical oncologist and member of the Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team ,...
Read More
December 18, 2024
Karmanos Cancer Institute Physicians Begin Prescribing New FDA-approved Radiofrequency Electromagnetic Device to Treat Advanced Liver Cancer

The Barbara Ann Karmanos Cancer Institute , the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that the new TheraBionic P1 device, an FDA-approved, at-home treatment , is now available to treat advanced liver cancer. Karmanos Cancer Center is the first institution worldwide to prescribe this treatment. The TheraBionic P1 device is a novel, handheld, portable device that produces low levels of 27.12 MHz radiofrequency electromagnetic fields, whic...
Read More
October 31, 2024
IN THE NEWS: Exploring Breakthroughs in Cancer Treatment with Dr. Boris C. Pasche, President & CEO at Karmanos Cancer Institute

Becker’s Healthcare Podcast Boris Pasche, M.D., Ph.D., FACP , president and CEO of the Barbara Ann Karmanos Cancer Institute, joined the Becker’s Healthcare Podcast to discuss advances in cancer treatment. He highlighted advances in theranostics, immunotherapy, and using electromagnetic radio frequencies to treat cancer. Dr. Pasche explained how these therapies are giving cancer patients more hope and improving outcomes. Your browser does not support the audio element. Download Podcast
Read More

Awards

2024 Crain's Healthcare Hero – Advancements in Care
2024 Becker's Oncology – Top Oncology Innovations & Research to Watch
Castle Connolly's Top Doctor since 2009
2006 Jeannik M. Littlefield-AACR Award in Metastatic Colon Cancer Research
2005 The Ohio State University Human Cancer Genetics Program Commemorative Medal
2003 Interdisciplinary Award, Northwestern Division of Hematology/Oncology

Professional Memberships

American Society for Clinical Investigation
American Society for Clinical Oncology
American Society of Hematology
American Associations of Cancer Institutes
American Clinical and Climatological Association

Publications

Michel, L.S., Liberal, V., Chatterjee, A., Kirchwegger, R., Pasche, B., Gerald, W., Dobles, M., Sorger, P.K., Murty, VV., Benezra, R. (2001). "MAD2 haploinsufficiency causes premature anaphase and chromosome instability in mammalian cells". Nature, 409, 355-359. PMID: 11201745
Pasche, B.*, Knobloch, T.J., Bian, Y, Liu, J., Phukan, S., Rosman, D., Kaklamani, V., Baddi, L., Siddiqui, F.S., Frankel, W.L., Prior, T.W., Schuller, D.E., Agrawal, A., Lang, J., Dolan, E., Vokes, E.E., Lane, W.S., Huang, C.-C., Caldes, T., Di Cristofano, A., Hampel, H., Nilsson, I., von Heijne, G., Fodde, R., Murty, V.V.V.S., de la Chapelle, A., Weghorst, C.W. (2005). "Somatic acquisition and signaling of TGFBR1*6A in cancer". Journal of the American Medical Association, 294, 1634-1646. PMID: 16204663
Valle, L., Serena-Acedo, T., Liyanarachchi, S., Hampel, H., Comeras, I., Li, Z., Zeng, Q., Zhang, H.T., Pennison, M., Sadim, M., *Pasche, B., *Tanner, S., *de la Chapelle, A. (2008). "Germline allele-specific expression of TGFBR1 predisposes to colorectal cancer". Science, 321, 1361-1365. PMID 1159397
Jimenez, H., Wang, M., Zimmerman, JW., Pennison, MJ., Sharma, S., Surratt, T., Xu, ZX., Brezovich, I., Absher, D., Myers, RM., DeYoung, B., Caudell, DL., Chen, D., Lo, HW., Lin, HK., Godwin, DW., Olivier, M., Ghanekar, A., Chen, K., Miller, LD., Gong, Y., Capstick, M., D'Agostino, RB, Jr, Munden, R., Merle, P., Barbault, A., Blackstock, AW., Bonkovsky, HL., Yang, GY., Jin, G., Liu, L., Zhang, W., Watabe, K., Blackman, CF., Pasche, B. (2019) Tumour-specific amplitudemodulated radiofrequency electromagnetic fields induce differentiation of hepatocellular carcinoma via targeting Cav3.2 T-type voltage-gated calcium channels and Ca2+ influx. EBioMedicine. pii: S2352-3964(19)30342-1. doi: 10.1016/j.ebiom.2019.05.034. Epub 2019 May 31. PMID: 3116027
Blackstock, AW., Benson, AB., Kudo, M., Jimenez, H., Achari, PF., McGrath, C., Kirchner, V., Wagner, LI, O'Connell, NS., Walker, K., Pasche, VK., D'Agostino, R., Barbault, A., Pasche, B (2021). Safety and efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma. 4open 4, 3 doi.org/10.1051/fopen/2021003

Provider Profile:
Boris Pasche, M.D., Ph.D., FACP